Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Allergan PLC, short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Turnover Ratios
Inventory turnover 2.18 2.20 2.20 2.33 2.30 2.59 2.44 2.35 2.36 2.40 2.30 2.08 2.03 2.59 2.55 3.55 4.18 4.76
Receivables turnover 5.75 5.04 5.25 5.08 5.75 5.50 5.67 5.85 6.08 5.50 5.51 5.39 5.80 5.76 5.57 5.56 6.00 6.28
Working capital turnover 395.48 287.30 58.26 21.12 27.78 10.43 9.97 8.39 4.46 1.46 0.56 52.49
Average No. Days
Average inventory processing period 167 166 166 157 159 141 150 155 155 152 159 176 180 141 143 103 87 77
Add: Average receivable collection period 64 72 70 72 63 66 64 62 60 66 66 68 63 63 65 66 61 58
Operating cycle 231 238 236 229 222 207 214 217 215 218 225 244 243 204 208 169 148 135

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Allergan PLC inventory turnover ratio improved from Q3 2019 to Q4 2019 but then deteriorated significantly from Q4 2019 to Q1 2020.
Receivables turnover An activity ratio equal to revenue divided by receivables. Allergan PLC receivables turnover ratio deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period.
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Allergan PLC number of days of receivables outstanding deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level.
Operating cycle Equal to average inventory processing period plus average receivables collection period. Allergan PLC operating cycle deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level.

Inventory Turnover

Allergan PLC, inventory turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights 623,100 704,000 639,000 652,300 497,800 590,000 596,800 481,800 522,800 580,900 586,500 550,200 450,400 479,700 462,200 441,500 477,400 417,300 1,242,900 2,130,100 1,020,100
Inventories 1,199,900 1,133,100 1,083,100 1,004,500 943,200 846,900 894,600 922,500 948,400 904,500 899,800 935,900 904,700 718,000 705,500 726,800 1,022,200 1,009,700 1,285,400 2,786,000 3,125,100
Short-term Activity Ratio
Inventory turnover1 2.18 2.20 2.20 2.33 2.30 2.59 2.44 2.35 2.36 2.40 2.30 2.08 2.03 2.59 2.55 3.55 4.18 4.76
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 4.17 4.10
Amgen Inc. 1.31 1.22
Bristol-Myers Squibb Co. 3.50 1.88
Eli Lilly & Co. 1.55 1.48
Gilead Sciences Inc. 4.75 5.07
Johnson & Johnson 3.16 3.05
Merck & Co. Inc. 2.46 2.36
Pfizer Inc. 1.15 1.23
Regeneron Pharmaceuticals Inc. 0.55 0.55
Thermo Fisher Scientific Inc. 4.14 4.22
Vertex Pharmaceuticals Inc. 3.29 3.27

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Inventory turnover = (Cost of sales, excludes amortization and impairment of acquired intangibles including product rightsQ1 2020 + Cost of sales, excludes amortization and impairment of acquired intangibles including product rightsQ4 2019 + Cost of sales, excludes amortization and impairment of acquired intangibles including product rightsQ3 2019 + Cost of sales, excludes amortization and impairment of acquired intangibles including product rightsQ2 2019) ÷ Inventories
= (623,100 + 704,000 + 639,000 + 652,300) ÷ 1,199,900 = 2.18

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Allergan PLC inventory turnover ratio improved from Q3 2019 to Q4 2019 but then deteriorated significantly from Q4 2019 to Q1 2020.

Receivables Turnover

Allergan PLC, receivables turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Net revenues 3,604,400 4,351,000 4,050,700 4,090,100 3,597,100 4,079,700 3,911,400 4,124,200 3,672,100 4,326,100 4,034,300 4,007,400 3,572,900 3,864,300 3,622,200 3,684,800 3,399,300 2,664,500 4,088,900 5,755,000 2,562,600
Accounts receivable, net of allowances for doubtful accounts and credit losses 2,800,600 3,192,300 3,012,300 3,086,300 2,731,200 2,868,100 2,826,900 2,760,800 2,639,200 2,899,000 2,808,600 2,795,900 2,542,000 2,531,000 2,398,500 2,490,500 2,652,800 2,401,600 2,143,200 4,420,100 3,992,800
Short-term Activity Ratio
Receivables turnover1 5.75 5.04 5.25 5.08 5.75 5.50 5.67 5.85 6.08 5.50 5.51 5.39 5.80 5.76 5.57 5.56 6.00 6.28
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 5.35 6.13
Amgen Inc. 4.55 5.47
Eli Lilly & Co. 4.52 4.91
Gilead Sciences Inc. 5.73 6.18
Johnson & Johnson 5.56 5.67
Merck & Co. Inc. 5.88 6.91
Pfizer Inc. 4.93 5.93
Regeneron Pharmaceuticals Inc. 2.72 2.94
Thermo Fisher Scientific Inc. 5.69 5.87
Vertex Pharmaceuticals Inc. 5.70 6.57

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Receivables turnover = (Net revenuesQ1 2020 + Net revenuesQ4 2019 + Net revenuesQ3 2019 + Net revenuesQ2 2019) ÷ Accounts receivable, net of allowances for doubtful accounts and credit losses
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100) ÷ 2,800,600 = 5.75

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Receivables turnover An activity ratio equal to revenue divided by receivables. Allergan PLC receivables turnover ratio deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level.

Working Capital Turnover

Allergan PLC, working capital turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Current assets 7,474,100 11,126,700 9,593,600 8,572,800 6,289,300 6,475,400 5,740,200 6,103,700 6,393,300 11,376,700 10,112,800 10,433,200 13,700,700 17,857,900 31,723,900 8,755,200 10,091,500 8,615,400 16,658,700 10,486,900 11,017,200
Less: Current liabilities 7,433,400 11,070,700 9,638,700 8,303,700 8,849,200 5,727,900 6,231,900 6,125,300 5,816,000 9,848,100 8,559,800 8,638,300 10,391,600 7,874,700 8,025,500 8,867,400 10,195,500 8,328,300 8,133,000 7,649,500 7,655,500
Working capital 40,700 56,000 (45,100) 269,100 (2,559,900) 747,500 (491,700) (21,600) 577,300 1,528,600 1,553,000 1,794,900 3,309,100 9,983,200 23,698,400 (112,200) (104,000) 287,100 8,525,700 2,837,400 3,361,700
 
Net revenues 3,604,400 4,351,000 4,050,700 4,090,100 3,597,100 4,079,700 3,911,400 4,124,200 3,672,100 4,326,100 4,034,300 4,007,400 3,572,900 3,864,300 3,622,200 3,684,800 3,399,300 2,664,500 4,088,900 5,755,000 2,562,600
Short-term Activity Ratio
Working capital turnover1 395.48 287.30 58.26 21.12 27.78 10.43 9.97 8.39 4.46 1.46 0.56 52.49
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. 0.97 0.98
Amgen Inc. 3.27 3.96
Bristol-Myers Squibb Co. 2.38 2.28
Eli Lilly & Co. 16.68 11.54
Gilead Sciences Inc. 1.24 1.08
Johnson & Johnson 7.85 8.81
Merck & Co. Inc. 17.87 8.90
Pfizer Inc. 57.45
Regeneron Pharmaceuticals Inc. 1.21 1.41
Thermo Fisher Scientific Inc. 3.54 4.48
Vertex Pharmaceuticals Inc. 1.23 1.19

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Working capital turnover = (Net revenuesQ1 2020 + Net revenuesQ4 2019 + Net revenuesQ3 2019 + Net revenuesQ2 2019) ÷ Working capital
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100) ÷ 40,700 = 395.48

2 Click competitor name to see calculations.


Average Inventory Processing Period

Allergan PLC, average inventory processing period calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Inventory turnover 2.18 2.20 2.20 2.33 2.30 2.59 2.44 2.35 2.36 2.40 2.30 2.08 2.03 2.59 2.55 3.55 4.18 4.76
Short-term Activity Ratio (no. days)
Average inventory processing period1 167 166 166 157 159 141 150 155 155 152 159 176 180 141 143 103 87 77
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 88 89
Amgen Inc. 279 300
Bristol-Myers Squibb Co. 104 194
Eli Lilly & Co. 236 247
Gilead Sciences Inc. 77 72
Johnson & Johnson 116 119
Merck & Co. Inc. 148 155
Pfizer Inc. 316 296
Regeneron Pharmaceuticals Inc. 659 661
Thermo Fisher Scientific Inc. 88 87
Vertex Pharmaceuticals Inc. 111 112

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.18 = 167

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period.

Average Receivable Collection Period

Allergan PLC, average receivable collection period calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Receivables turnover 5.75 5.04 5.25 5.08 5.75 5.50 5.67 5.85 6.08 5.50 5.51 5.39 5.80 5.76 5.57 5.56 6.00 6.28
Short-term Activity Ratio (no. days)
Average receivable collection period1 64 72 70 72 63 66 64 62 60 66 66 68 63 63 65 66 61 58
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 68 60
Amgen Inc. 80 67
Eli Lilly & Co. 81 74
Gilead Sciences Inc. 64 59
Johnson & Johnson 66 64
Merck & Co. Inc. 62 53
Pfizer Inc. 74 62
Regeneron Pharmaceuticals Inc. 134 124
Thermo Fisher Scientific Inc. 64 62
Vertex Pharmaceuticals Inc. 64 56

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.75 = 64

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Allergan PLC number of days of receivables outstanding deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level.

Operating Cycle

Allergan PLC, operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Average inventory processing period 167 166 166 157 159 141 150 155 155 152 159 176 180 141 143 103 87 77
Average receivable collection period 64 72 70 72 63 66 64 62 60 66 66 68 63 63 65 66 61 58
Short-term Activity Ratio
Operating cycle1 231 238 236 229 222 207 214 217 215 218 225 244 243 204 208 169 148 135
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 156 149
Amgen Inc. 359 367
Eli Lilly & Co. 317 321
Gilead Sciences Inc. 141 131
Johnson & Johnson 182 183
Merck & Co. Inc. 210 208
Pfizer Inc. 390 358
Regeneron Pharmaceuticals Inc. 793 785
Thermo Fisher Scientific Inc. 152 149
Vertex Pharmaceuticals Inc. 175 168

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

1 Q1 2020 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 167 + 64 = 231

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Operating cycle Equal to average inventory processing period plus average receivables collection period. Allergan PLC operating cycle deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level.